Result of AGM
RNS & Investor News
Non-Exclusive UK distribution agreement for SlimBiome®
24 April 2018
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a non-exclusive distribution agreement with Cambridge Commodities Ltd ("CCL"). The agreement grants CCL a non-exclusive licence to distribute OptiBiotix's SlimBiome® weight management technology in the United Kingdom.
CCL, a privately held company, is the leading supplier of nutritional ingredients to the sports, health & wellbeing, animal nutrition and food & beverage industries. CCL has 10 sales offices which cover the UK, Europe, USA and South Africa with a multimillion pound annual turnover. SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be purchased from OptiBiotix and distributed by CCL as a specialised branded functional ingredient.
This agreement, with one of the UK's leading ingredients suppliers is complementary to the agreement with Knighton Food Ltd (announced on 1 November 2017), as it extends SlimBiome's® commercial reach into new application areas where CCL has specific sector expertise, such as sports, health & wellbeing and ingredients sectors. CCL will use their best endeavours to promote and expand the distribution of SlimBiome® across their network of customers and is a further step in extending the opportunities offered by SlimBiome® into new markets.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a distribution agreement with CCL. We chose them due to their leading market position and expertise in commercialising value added speciality ingredients like SlimBiome® to sports, health & wellbeing industries and major UK retailers. We believe working with CCL, and similar partners around the world, provides the best opportunity to expand the range of applications for SlimBiome® to a wide range of industry sectors. This agreement is another step in our low cost approach to growing revenues by building manufacturing, formulation/application and distribution partnerships which provide revenues across the whole value chain in multiple industry sectors."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP||Tel: 020 7213 0880|
|Liam Murray / Jo Turner|
|finnCap Broker||Tel: 020 7220 0500|
|Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
Abigail Wayne (Corporate Broking)
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020